Description: Phase 1/2a Dose Escalation, Finding and Expansion Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of PF-07104091 as a Single Agent and in Combination Therapy.
Target Patient Population: Small cell Lung Cancer, Platinum Resistant Ovarian, Non-small cell Lung Cancer; in combination with palbociclib and fulvestrant for HR+ HER2- Metastatic Breast Cancer (3rd line plus)
Study Design: Drug is given orally twice daily.